CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Exeliom Biosciences is developing a novel treatment for Crohn's disease using a unique bacterium to achieve long-term remission without side effects. This innovative approach aims to improve patient quality of life and reduce healthcare costs associated with the disease.
Crohn's disease is a Chronnic Inflammatory Bowel disease affecting over 1.4 million people worldwide.
It is the fourth chronic condition impacting the most severely patients’ quality of life, ahead of cancer, visual impairments, and chronic respiratory conditions.
Crohn’s disease is an intestinal disorder causing chronic inflammation of the gastrointestinal tract.
It is mainly diagnosed in young people, from 15 to 40 years old.
Patients experience excruciating symptoms such as abdominal pain, d…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
